ClinConnect ClinConnect Logo
Search / Trial NCT06068517

Closed Incision Negative Pressure Wound Therapy for the Prevention of Surgical Site Infections in Abdominal Surgery

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Sep 28, 2023

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help prevent surgical site infections (SSIs) after abdominal surgery using a method called closed incision negative pressure wound therapy (ciNPWT). SSIs are common complications that can make recovery harder and cost more for patients. ciNPWT uses a gentle vacuum to help keep the surgical incision clean and promote healing. The main goal of this study is to find out if using this therapy can reduce the risk of infections for patients who have had surgery on their abdomen.

To participate in this trial, individuals must be adults over 18 years old who are undergoing certain types of abdominal surgeries, such as elective or emergency laparotomies (a type of surgery where the abdomen is opened). The surgical incision must be at least 10 centimeters long and classified as clean or clean-contaminated. Patients with dirty or infected wounds, those under 18, or individuals with allergies to silver will not be eligible. Participants in the trial will undergo standard surgical procedures and, if selected, may receive the ciNPWT treatment to see how it affects their recovery. The trial is not yet recruiting, so there will be more information available as it begins.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Elective or emergency laparotomy, or laparoscopy converted to laparotomy, including surgery for complications after elective operations
  • Incision length ≥ 10 cm
  • Centers for Disease Control and Prevention (CDC) wound class 1 and 2 (clean, clean-contaminated)
  • Abdominal closure with or without mesh implantation
  • Primary abdominal closure or closure after open abdomen treatment
  • Age over 18 years
  • Written informed consent
  • Exclusion Criteria:
  • Age ≤ 18 years
  • CDC wound class 4 (dirty/infected wound)
  • Organ transplantation
  • Sensitivity or allergy to silver

About Insel Gruppe Ag, University Hospital Bern

Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.

Locations

Bern, , Switzerland

Patients applied

0 patients applied

Trial Officials

Tobias Haltmeier, MD

Principal Investigator

Inselspital, Bern University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported